Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026

More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America

C-FORWARD and C-BEYOND Represent the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for the Treatment of HCV

BOSTON, June 25, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced completion of patient enrollment in C-FORWARD, its Phase 3 clinical trial outside North America, evaluating the regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) infection. The anticipated topline results from C-BEYOND, the Phase 3 trial conducted in the US and Canada, remain on track for mid-year 2026.

C-FORWARD enrolled more than 880 treatment-naïve patients across approximately 120 clinical sites in 17 countries. The trial is evaluating the fixed-dose combination regimen of BEM/RZR against a current standard of care – the fixed-dose combination regimen of sofosbuvir and velpatasvir – in patients with chronic HCV infection. Topline results from C-FORWARD are expected around year-end 2026. Notably, patients enrolled in C-FORWARD have a diverse range of HCV genotypes, including genotypes more commonly observed outside North America, supporting the potential for a broad treatment label.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.